Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.58 |
| ▸ | GLA | P06280 | 1/20 | 0.58 |
| ▸ | CA3 | P07451 | 1/20 | 0.58 |
| ▸ | CA4 | P22748 | 1/20 | 0.58 |
| ▸ | CA9 | Q16790 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.58 |
| ▸ | DRD2 | P14416 | 2/20 | 0.42 |
| ▸ | DRD1 | P21728 | 2/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | DRD5 | P21918 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | MMP3 | P08254 | 1/20 | 0.42 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenol SCHEMBL5875014 | 0.97 | CA12 (0.55) | CA12CA1CA2GLACA3 | |
| Phenol SCHEMBL29140824 | 0.95 | CA12 (0.52) | CA12CA1CA2GLACA3 | |
| Phenol SCHEMBL28163778 | 0.95 | CA12 (0.52) | CA12CA1CA2GLACA3 | |
| Phenol SCHEMBL27919347 | 0.92 | CA12 (0.69) | CA12CA1CA2GLACA3 | |
| Phenol SCHEMBL5874295 | 0.89 | CA12 (0.65) | CA12CA1CA2GLACA3 | |
| Phenol SCHEMBL10791210 | 0.89 | CA12 (0.65) | CA12CA1CA2GLACA3 | |
| Phenol SCHEMBL10791213 | 0.89 | CA12 (0.65) | CA12CA1CA2GLACA3 | |
| Phenol SCHEMBL27280139 | 0.86 | CA12 (0.61) | CA12CA1CA2GLACA3 | |
| Phenol SCHEMBL28217458 | 0.86 | CA12 (0.61) | CA12CA1CA2GLACA3 | |
| Hydroquinone SCHEMBL11763246 | 0.86 | ALDH1A1 (0.50) | CA12CA1CA2CA3CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111018901-B | Zanamivir and ranamivir intermediate and synthesis method thereof | 中国科学院上海有机化学研究所 | 2021-09-03 | — | — | CN | claimed |
| CN-111116567-A | Zanamivir and ranamivir intermediate and synthesis method thereof | 中国科学院上海有机化学研究所 | 2020-05-08 | — | — | CN | claimed |
| CN-111018901-A | Zanamivir and ranamivir intermediate and synthesis method thereof | 中国科学院上海有机化学研究所 | 2020-04-17 | — | — | CN | claimed |
| CN-104418876-B | Zanamivir and ranamivir intermediate and synthesis method thereof | 中国科学院上海有机化学研究所 | 2019-05-17 | — | — | CN | claimed |
| CN-111116567-B | Zanamivir and ranamivir intermediates and synthesis method thereof | 中国科学院上海有机化学研究所 | 2023-10-10 | — | — | CN | disclosed |
| CN-111116533-B | Zanamivir and ranamivir intermediate and synthesis method thereof | 中国科学院上海有机化学研究所 | 2022-11-22 | — | — | CN | disclosed |
| CN-114213425-A | Preparation process of carboxyl-X-rhodamine | 合肥华纳生物医药科技有限公司 | 2022-03-22 | — | — | CN | disclosed |
| CN-114213425-A | Preparation process of carboxyl-X-rhodamine | 合肥华纳生物医药科技有限公司 | 2022-03-22 | — | — | CN | disclosed |
| CN-111018901-B | Zanamivir and ranamivir intermediate and synthesis method thereof | 中国科学院上海有机化学研究所 | 2021-09-03 | — | — | CN | disclosed |
| US-20210017211-A1 | OLIGOSACCHARIDE C-GLYCOSIDE DERIVATIVES | OKINAWA INSTITUTE OF SCIENCE AND TECHNOLOGY SCHOOL CORPORATION (JP) | 2021-01-21 | — | — | US | disclosed |
| US-7951793-B2 | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-05-31 | — | — | US | disclosed |
| EP-1656368-A4 | SUBSTITUTED HERTOCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2009-08-26 | — | — | EP | disclosed |
| US-20070287713-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY | 2007-12-13 | — | — | US | disclosed |
| US-7279485-B2 | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-10-09 | — | — | US | disclosed |
| EP-1656368-A2 | SUBSTITUTED HERTOCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | Bristol-Myers Squibb Company (US) | 2006-05-17 | — | — | EP | disclosed |
| US-20040063700-A1 | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-01 | — | — | US | disclosed |
| WO-2004004665-A2 | SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-01-15 | — | — | WO | disclosed |
| US-6458787-B1 | NOVEL PYRROLIDINE COMPOUNDS THAT ARE POTENT AND SELECTIVE INHIBITORS OF PDE4, AS WELL AS METHODS OF MAKING THE SAME, ARE DISCLOSED. USE OF THE COMPOUNDS IN THE TREATMENT OF INFLAMMATORY DISEASES AND OTHER DISEASES INVOLVING ELEVATED | ICOS CORPORATION | 2002-10-01 | — | — | US | disclosed |
| US-6258833-B1 | ENZYME INHIBITORS AND ANTIINFLAMMATORY AGENTS | ICOS CORPORATION | 2001-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287713-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | PYM1, GPR119, GLP1R | CA12 2479/4885CA1 2862/4885CA2 877/4885 |
| US-20210017211-A1 | OLIGOSACCHARIDE C-GLYCOSIDE DERIVATIVES | OSTC, FUT6, FUT5 | CA12 155/4885CA1 1659/4885CA2 3004/4885 |
| US-20040063700-A1 | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method | GPR119, SLC5A2, GLP1R | CA12 2448/4885CA1 3042/4885CA2 720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.